Heterogeneity of Oral Carcinogenesis: From PrEneoplasia to Invasive Squamous Cell Carcinoma

Starting soon · Not applicable

Conditions studied: Oral Squamous Cell Carcinomas, Oral Potentially Malignant Disorder

In brief

The goal of this project is to characterise the heterogeneity of all cell populations (tumour cells, stromal and immune microenvironment) present in the tumor and their normal (and OPMD) counterparts by scRNAseq in OSCC patients. Additionally, the study will evaluate the effectiveness of non-invasive cytobrushes as a diagnostic tool compared to traditional biopsies.

Key facts

Study ID: NCT07579507
Run by: Centre Leon Berard
People needed: 150
Starts: 2026-06-01
Expected to finish: 2035-03-01
Last updated by the study team: 2026-05-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

I1: Male or female at least 18 years old.
I2: For Cohort A: patients with OSCC who undergo surgery. For cohorts B and C: patients with OPMD.
I3: Patient who has agreed to participate in this research and sign consent.
I4: Patient affiliated to a medical insurance.
I5: Patient who have not previously received any anticancer treatment (radiotherapy, chemotherapy, or immunotherapy)

You may not qualify if…

NI1: For cohorts B and C: Patient at high risk of bleeding, such as those receiving anticoagulant or antiplatelet therapy, those with coagulation disorders, or those with a history of severe bleeding within the two weeks prior to enrollment.
NI2: Pregnant or nursing woman.
NI3: Contraindication to general anesthesia.
NI4: Suspicion of rare tumor of particular histology other than squamous cell carcinoma (Sarcoma...).
NI5: Patient under curatorial or guardianship or placed under the protection of justice.

Where it is running

Centre Léon Bérard — Lyon, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.